Hillrom's retreat from $375M Bardy Diagnostics acquisition countered in court
Mobi Health News
MARCH 3, 2021
Hillrom says that lower-than-expected reimbursement rates proposed in late January void the deal. But the cardiac-monitoring device maker asserts they were accounted for during negotiations.
Let's personalize your content